Clinical Policy: Depemokimab-ulaa (Exdensur)
Customize your policy alerts
Sign up for QualChoice Policy HIM.PA.179 alerts
Get alerted when Policy HIM.PA.179 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, and coverage criteria for Exdensur (depemokimab-ulaa) as add-on maintenance treatment of severe eosinophilic asthma for eligible members; applies to QualChoice HIM line of business.
Added HCPCS code J2361 and removed miscellaneous/unlisted codes (J3590 and others).
Added HCPCS code J2361.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.